Kate Townsend Creasy

Dr. Kate Townsend Creasy

Biobehavioral Health Sciences, University of Pennsylvania, Philadelphia, Mississippi, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MVMarijana Vujkovic
Marijana Vujkovic
SRShweta Ramdas
Shweta Ramdas
KLKim M. Lorenz
Kim M. Lorenz
XGXiuqing Guo
Xiuqing Guo
RDRebecca Darlay
Rebecca Darlay
KCKyong-Mi Chang
Kyong-Mi Chang

9 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
CSCarolin V. Schneider
Carolin V. Schneider
TLTang Li
Tang Li
DZDavid Zhang
David Zhang
AMAnya I. Mezina
Anya I. Mezina
PRPuru Rattan
Puru Rattan
DRDaniel J. Rader
Daniel J. Rader
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidity in people with and without diabetes, but it is underdiagnosed, posing challenges for research and clinical management. Here, we determine if natural language processing (NLP) of data in the electronic health record (EHR) could identify undiagnosed patients with hepatic steatosis based on pathology and radiology reports. A rule-based NLP algorithm was built using a Linguamatics literature text mining tool to search 2.15 million pathology report and 2.7 million imaging reports in the Penn Medicine EHR from November 2014, through December 2020, for evidence of hepatic steatosis. For quality control, two independent physicians manually reviewed randomly chosen biopsy and imaging reports (n = 353, PPV 99.7%). After exclusion of individuals with other causes of hepatic steatosis, 3007 patients with biopsy-proven NAFLD and 42,083 patients with imaging-proven NAFLD were identified. Interestingly, elevated ALT was not a sensitive predictor of the presence of steatosis, and only half of the biopsied patients with steatosis ever received an ICD diagnosis code for the presence of NAFLD/NASH. There was a robust association for PNPLA3 and TM6SF2 risk alleles and steatosis identified by NLP. We identified 234 disorders that were significantly over- or underrepresented in all subjects with steatosis and identified changes in serum markers (e.g., GGT) associated with presence of steatosis. This study demonstrates clear feasibility of NLP-based approaches to identify patients whose steatosis was indicated in imaging and pathology reports within a large healthcare system and uncovers undercoding of NAFLD in the general population. Identification of patients at risk could link them to improved care and outcomes. The study was funded by US and German funding sources that did provide financial support only and had no influence or control over the research process.

13 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGregory J. Salimando
Gregory J. Salimando
STSébastien Tremblay
Sébastien Tremblay
BKBlake A. Kimmey
Blake A. Kimmey
JLJia Li
Jia Li
SRSophie A. Rogers
Sophie A. Rogers
GCGregory Corder
Gregory Corder
With concurrent global epidemics of chronic pain and opioid use disorders, there is a critical need to identify, target and manipulate specific cell populations expressing the mu-opioid receptor (MOR). However, available tools and transgenic models for gaining long-term genetic access to MOR+ neural cell types and circuits involved in modulating pain, analgesia and addiction across species are limited. To address this, we developed a catalog of MOR promoter (MORp) based constructs packaged into adeno-associated viral vectors that drive transgene expression in MOR+ cells. MORp constructs designed from promoter regions upstream of the mouse Oprm1 gene (mMORp) were validated for transduction efficiency and selectivity in endogenous MOR+ neurons in the brain, spinal cord, and periphery of mice, with additional studies revealing robust expression in rats, shrews, and human induced pluripotent stem cell (iPSC)-derived nociceptors. The use of mMORp for in vivo fiber photometry, behavioral chemogenetics, and intersectional genetic strategies is also demonstrated. Lastly, a human designed MORp (hMORp) efficiently transduced macaque cortical OPRM1+ cells. Together, our MORp toolkit provides researchers cell type specific genetic access to target and functionally manipulate mu-opioidergic neurons across a range of vertebrate species and translational models for pain, addiction, and neuropsychiatric disorders.

7 May 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
KSKatharina Sophie Seeling
Katharina Sophie Seeling
LHLeonida Hehl
Leonida Hehl
MVMara Sophie Vell
Mara Sophie Vell
MRMiriam Daphne Rendel
Miriam Daphne Rendel
Kate Townsend CreasyKate Townsend Creasy
Kate Townsend Creasy
CSCarolin V. Schneider
Carolin V. Schneider
Background: Irritable bowel syndrome (IBS) is one of the most common functional digestive disorders. Our understanding about its comorbidities, biomarkers, or long‐term risks is still incomplete.Objective: To characterize comorbidities and biomarkers for IBS and establish the effect of IBS on overall‐ and cause specific mortality.Methods: We analyzed data from the population‐based cohort of the UK Biobank (UKB) with 493,974 participants, including self‐reported physician‐diagnosed (n = 20,603) and ICD‐10 diagnosed (n = 7656) IBS patients, with a mean follow‐up of 11 years. We performed a phenome‐wide association study (PheWAS) and competing risk analysis to characterize common clinical features in IBS patients.Results: In PheWAS analyses, 260 PheCodes were significantly overrepresented in self‐reported physician‐diagnosed IBS patients, 633 in patients with ICD‐10 diagnosed IBS (ICD‐10‐IBS), with 221 (40%) overlapping. In addition to gastrointestinal diseases, psychiatric, musculoskeletal, and endocrine/metabolic disorders represented the most strongly associated PheCodes in IBS patients. Self‐reported physician‐diagnosed IBS was not associated with increased overall mortality and the risk of death from cancer was decreased (hazard ratio [HR] = 0.78 [95% CI = 0.7–0.9]). Lastly, we evaluated changes in serum metabolites in IBS patients and identified glycoprotein acetyls (GlycA) as a potential biomarker in IBS. One standard deviation increase in GlycA raised the risk of self‐reported IBS/ICD‐10 coded by 9%–20% (odds ratio [OR] = 1.09 [95% CI = 1.1–1.1]/OR = 1.20 [95% CI = 1.1–1.3]) and the risk of overall mortality in ICD‐10‐IBS patients by 28% (HR = 1.28 [95% CI = 1.1–1.5]).Conclusion: Our large‐scale association study determined IBS patients having an increased risk of several different comorbidities and that GlycA was increased in IBS patients.

7 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
COCorinna S. Oswell
Corinna S. Oswell
SRSophie A. Rogers
Sophie A. Rogers
JJJustin G. James
Justin G. James
NMNora M. McCall
Nora M. McCall
AHAlex I. Hsu
Alex I. Hsu
GCGregory Corder
Gregory Corder
The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, but how opioid analgesics modulate this cortical circuit remains unclear1. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviours and is selectively modulated by morphine. Using deep learning behavioural analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective–motivational behaviours without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired chemogenetic gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic μ-opioid receptor promoter to drive inhibition2. This opioid-mimetic chemogenetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management that targets a key nociceptive cortical opioid circuit with safe, on-demand analgesia.

11 February 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
KSKai Markus Schneider
Kai Markus Schneider
FCFeng Cao
Feng Cao
HHHelen Ye Rim Huang
Helen Ye Rim Huang
LCLanlan Chen
Lanlan Chen
YCYazhou Chen
Yazhou Chen
CSCarolin V. Schneider
Carolin V. Schneider
Background: The recent consensus statement redefined steatotic liver diseases. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol‐related liver disease (MetALD) now represent distinct disease entities. However, biomarkers that differentiate MASLD and MetALD remain largely unknown.Aims: To identify lipidomic biomarkers with discriminatory potential for distinguishing MetALD from MASLD.Methods: Using the UK Biobank dataset, 40,534 people with available MRI liver scans were analysed. A total of, 11,217 cases with a proton density fat fraction (PDFF) ≥ 5% were identified as having steatotic liver disease. Among these, lipidomic profiles were obtained for 5539 MASLD and 462 MetALD cases. A total of, 250 plasma lipidomic and metabolomic parameters were analysed. Mendelian randomisation (MR) analysis was used to confirm the association between alcohol consumption and the lipidomic biomarkers.Results: When comparing the top 30 differentially expressed lipidomic biomarkers predicting MetALD compared to MASLD, the majority were related to HDL and were significantly overrepresented at both analysed time points. The top five metabolites were: acetoacetate, 3‐hydroxybutyrate, phospholipids in Large HDL, concentration of large HDL particles, free cholesterol in large HDL. The sensitivity analysis comparing alcohol‐related liver disease to MASLD revealed similar associations, suggesting that the HDL signature is stable over time. Additionally, MR analysis further confirmed that alcohol consumption was associated with increased levels of HDL‐related metabolites.Conclusion: Our findings indicate that HDL‐centric lipidomic markers, particularly those within the larger and medium HDL subfraction, may differentiate MetALD from MASLD. Further longitudinal and experimental studies are warranted to validate these findings and assess their clinical implications.